Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ACET.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 120.14M
March 31, 2026 140.06M
December 31, 2025 159.21M
September 30, 2025 109.14M
June 30, 2025 133.37M
March 31, 2025 161.45M
December 31, 2024 186.61M
September 30, 2024 211.53M
June 30, 2024 235.11M
March 31, 2024 258.80M
December 31, 2023 170.18M
September 30, 2023 194.68M
June 30, 2023 239.06M
March 31, 2023 266.22M
December 31, 2022 292.34M
September 30, 2022 317.66M
June 30, 2022 293.27M
March 31, 2022 311.08M
Date Value
December 31, 2021 303.13M
September 30, 2021 217.22M
June 30, 2021 228.34M
March 31, 2021 236.26M
December 31, 2020 109.83M
September 30, 2020 116.93M
June 30, 2020 70.74M
March 31, 2020 75.62M
December 31, 2019 -60.37M
September 30, 2019 109.76M
June 30, 2019 126.94M
March 31, 2019 140.46M
December 31, 2018 104.20M
September 30, 2018 109.34M
June 30, 2018 117.16M
March 31, 2018 130.38M
December 31, 2017 49.69M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics